Therapeutic revolution for inoperable stage Ⅲ non-small cell lung cancer in the immune era

作者：Jiakang Li; Jingyan Xu; Mingyi Yang; Qing Zhou^*

来源：Cancer Biology & Medicine, 2022, 19(05): 569-572.

<正>The PACIFIC study ushered in a “tsunami-like” therapeutic revolution for stage Ⅲ inoperable non-small cell lung cancer(NSCLC) In the past, chemoradiotherapy(CRT) has been the standard of care for inoperable stage Ⅲ NSCLC. Concurrent chemoradiotherapy(cCRT), if tolerable in patients, is the optimal treatment regimen.

• 单位
  华南理工大学; 南方医科大学